STAT

Opinion: CVS-Aetna deal will save money by cutting supply chain negotiations

Consumers aren't happy with the current health care climate, and the industry must change in response. The CVS-Aetna deal is one sign of that change.
Source: Justin Sullivan/Getty Images

CVS’s $69 billion acquisition of Aetna continues to lurch toward closure — the deal doesn’t yet have the full green light — marking one of the health care industry’s largest transactions to date. CVS has promised consumers an improved experience and lower costs.

has ramifications far beyond the current customers of CVS and Aetna. It should pave the way for a new kind of health care by addressing major inefficiencies in our overly complex health care system. If everything goes as planned, the deal will cut spending in the pharmaceutical supply

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Cigna Biosimilar Plans, A Vertex Deal In South Africa, And More
Cigna plans to make copies of AbbVie's Humira arthritis drug available with no out-of-pocket payment to eligible patients in the U.S.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About CVS And Humira Biosimilars, Schumer’s Broken Insulin Promise, And More
New prescriptions for biosimilar versions of Humira, one of the best-selling drugs in the U.S., surged to 36% from just 5% during the first week of April.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.

Related Books & Audiobooks